目的 探討果糖二磷酸鈉注射液聯(lián)合硫酸氫氯吡格雷片治療急性心肌梗死的臨床療效。方法 選擇2019年6月—2020年6月在安陽市人民醫(yī)院治療的118例急性心肌梗死患者，根據(jù)用藥的差別分為對照組（59例）和治療組（59例）。對照組口服硫酸氫氯吡格雷片，起始劑量為300 mg/次，然后75 mg/次，2次/d；治療組在對照組的基礎上靜脈滴注果糖二磷酸鈉注射液，100 mL/次，1次/d。兩組患者均治療2周。觀察兩組患者臨床療效，比較治療前后兩組患者心功能指標左心室射血分數(shù)（LVEF）、左心室收縮末期內(nèi)徑（LVESD）、左心室收縮末期容積（LVESV）、左室舒張末期內(nèi)經(jīng)（LVEDD），血清學指標心肌肌鈣蛋白T（cTnT）、基質金屬蛋白酶-9（MMP-9）、類胰島素生長因子-1（IGF-1）、N端腦鈉肽前體（NT-proBNP）和心肌營養(yǎng)素-1（CT-1）水平，及QRS積分和心肌梗死面積。結果 經(jīng)治療，對照組總有效率為83.05%，顯著低于治療組的98.31%（P<0.05）。治療后，兩組LVEDD、LVESV和LVESD明顯降低，而LVEE明顯升高（P<0.05），且治療組好轉程度最明顯（P<0.05）。治療后，兩組cTnT、NT-proBNP和MMP-9明顯降低，而CT-1和IGF-1明顯升高（P<0.05），且治療組好轉最明顯（P<0.05）。治療后，兩組QRS積分、心肌梗死面積都明顯減?。?i>P<0.05），且治療組減小程度最明顯（P<0.05）。結論 果糖二磷酸鈉注射液聯(lián)合硫酸氫氯吡格雷片治療急性心肌梗死可有效改善患者心功能，降低機體炎癥反應，保護受損的心肌細胞，降低心肌重塑風險。

Objective To investigate the clinical efficacy of sodium fructose diphosphate combined with clopidogrel hydrogen sulphate in treatment of acute myocardial infarction. Methods Patients (118 cases) with acute myocardial infarction in the People’s Hospital of Anyang City from June 2019 to June 2020 were divided into control (59 cases) and treatment (59 cases) groups based on different treatments. Patients in the control group were po administered with Clopidogrel Hydrogen Sulphate Tablets, and the initial dose was 300 mg/time, then 75 mg/time, twice daily. Patients in the treatment group were iv administered with Sodium Fructose Diphosphate Injection on the basis of the control group, 100 mL/time, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the cardiac function indexes of LVEDD, LVESV, LVESD, and LVEE, the serum levels of cTnT, NT-proBNP, MMP-9, CT-1 and IGF-1, and QRS scores and myocardial infarct area in two groups before and after treatment were compared. Results After treatment, the effective rate of the control group was 83.05%, which was significantly lower than 98.31% in the treatment group (P<0.05). After treatment, LVEDD, LVESV, and LVESD in the two groups were significantly decreased, while LVEE were significantly increased (P<0.05), and the improvement in the treatment group was most obviously improved (P<0.05). After treatment, cTnT, NT-proBNP and MMP-9 in the two groups were significantly decreased (P<0.05), while CT-1 and IGF-1 were significantly increased (P<0.05), and the improvement in the treatment group was most obviously improved (P<0.05). After treatment, the QRS score and myocardial infarction area in two groups were significantly decreased (P<0.05), especially in the treatment group (P<0.05). Conclusion Sodium fructose diphosphate combined with clopidogrel hydrogen sulphate in treatment of acute myocardial infarction can effectively improve cardiac function, reduce the inflammatory response, protect damaged cardiomyocytes, and reduce the risk of myocardial remodeling.

R972